PPM Oost
Laan van Malkenschoten 40, Apeldoorn, Gelderland, 7333 NP, The Netherlands
Overview
PPM Oost invests in promising businesses. Companies that are pioneers or give the regional economy a boost. They focus on the market sectors health, technology and the food industry. But other innovative companies are also welcome, of course. PPM Oost invests in starters, early phases, expansion, bridge financing, management follow-up, restructuring, company succession, management buy-outs and buy-ins.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- CleanTech
- Venture Capital
Investment portfolio
- Mimetas
Participated · Equity · Oct 2014
Mimetas develops organ-on-a-chip products and tissue models, centered on its OrganoPlate® platform which supports 3D cell culture under continuous perfusion with membrane-free co-culture and epithelial and endothelial tubules. The company develops and validates customized disease, toxicology and transport models and has models for the kidney, liver, gut, brain and a range of oncological applications. Since its commercial launch in 2014 it has grown its customer base to half of the global top-50 pharmaceutical companies and also serves chemical, food and consumer goods firms; it also has operations in Japan. Mimetas was co-founded by Jos Joore and Paul Vulto. The company will use the proceeds from the recent financing to expand its global commercial presence with the OrganoPlate® platform, broaden its product portfolio, establish tissue production facilities, develop novel OrganoPlate® products and expand into clinical market segments, including personalized medicine. Mimetas recently raised a Series B financing to support these plans. Mimetas B.V. is a Leiden, The Netherlands-based developer of organ-on-a-chip technology. Led by co-founder and Chief Business Officer Jos Joore, the company develops predictive Organ-on-a-Chip cell culture models for tailored medicines. Its OrganoPlates™ feature organotypic screening models that can be screened at high throughput. Mimetas has a range of disease, toxicology and ADME models in its pipeline in various stages of development and validation. The company raised $5.2m in funding from Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost), which joined forces with national and regional partners. It intends to use the funds for development and sales of its 3D disease- and tissue-modelling technologies.
- CWR Mobility
Participated · Series B · Jan 2011
CWR Mobility provides mobile solutions for Microsoft Dynamics CRM, offering a multi-platform product suite including its flagship CWR Mobile CRM. Its solution supports iPhone, Windows Phone and BlackBerry devices, and the company plans product development to add iPad and Android support. CWR reported accelerated demand and completed a strong 2010, adding key executives and delivering product releases including version 4.2 and a Dynamics CRM to Exchange Server Connector. The company positions itself as a leader in enabling sales and service teams to drive business results through rapidly deployed mobile applications. Management intends to use new capital to build sales and partner coverage in North America, expand coverage in EMEA and APAC, and amplify marketing and demand generation. CWR secured $1.5M in Series B financing to support these initiatives.
Team
No current team members are available.